Emmaus Life Sciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.2M
- Price
- $0.0603
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.10%
- Volume
- 10.8K
About
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Quick stats
Shares outstanding70.2M
Computed float41.3M
Float / shares58.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000822370
AI Summary
AI-generated1/3
minorbullishpartnership
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
Emmaus entered into an exclusive option agreement with Cedars-Sinai to evaluate L-glutamine oral powder in combination with chemotherapy for pancreatic cancer.
The agreement builds on results from the GlutaPanc trial recently published in Nature Cancer, targeting Pancreatic Ductal Adenocarcinoma.
CEO Willis Lee emphasized the move as a step to explore new treatment options beyond the company's established sickle cell disease focus.
Red flags
- Safety and efficacy of L-glutamine for PDAC have not been established
- No guarantee of regulatory approval for this investigational use